What happened
FDA states that its March 30 to April 2, 2026, inspection of Happy Farm Botanicals’ OTC drug facility found significant CGMP violations. The firm did not perform specific identity testing on incoming raw materials and components, including APIs, before use; one API lot received only organoleptic testing and was used in finished batches. FDA also found a lapsed supplier requalification and no adequate validation of supplier test analyses. The stability program lacked adequate chemical and microbiological support for labeled expiry periods: accelerated studies lacked controlled humidity records, several timepoints were unavailable, and failing viscosity results in accelerated and long-term studies were not investigated. FDA’s quality unit findings included absent process validation for OTC products, absent cleaning validation for non-dedicated equipment, inadequate investigation and CAPA for recurring gasket seal failures, and inappropriate API content release limits. FDA deemed the firm’s response inadequate and noted that process and cleaning validation commitments from the 2024 inspection remained incomplete. The firm reported plans to cease production of the specified drugs at this facility.
Why it matters
From a GMP manufacturing perspective, inadequate component identity testing and supplier qualification may leave the firm without scientific evidence that materials meet specifications before use. Stability gaps and uninvestigated failures may weaken support for storage conditions and labeled expiration dates. Missing process and cleaning validation may limit assurance that manufacturing remains controlled and that shared equipment is consistently cleaned. Recurring equipment failures, inadequate investigations, and incomplete prior commitments may indicate broader weaknesses in quality-unit oversight, CAPA execution, and management control.
Key topics: Missing API identity testing and lapsed supplier requalification, Unsupported stability program and uninvestigated viscosity failures, Uncompleted process and cleaning validation under inadequate quality unit oversight